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Abstract: Previous studies suggested that the incidental use of b-
blockers might influence clinical outcome in solid tumors. We assessed
the correlation between the incidental use of b-blockers and clinical
outcome in colorectal cancer patients treated with first-line chemother-
apy alone or in combination with bevacizumab in metastatic colorectal
cancer patients.
We collected data from 235 metastatic colorectal cancer patients
treated with first-line chemotherapy alone (128 patients) or with bev-
acizumab (107 patients). Patients were stratified for clinical factors such
as b-blockers use, age, sex, and site of metastases, previous adjuvant
chemotherapy and ECOG performance status.
In the chemotherapy alone group patients receiving b-blockers
showed an improved overall survival (median OS 41.3 vs 25.7 months,
P¼ 0.03, HR: 2.26, 95% CI: 1.05–3.24). A significant relationship with
improved response rate was also evident for B-blocker users
(P¼ 0.044).
On the contrary in the b-blockers users group treated with che-
motherapy in combination with bevacizumab we observed a trend
toward a worse overall survival although nonstatistically significant
(median OS 18.5 vs 23.6 months, HR: 0. 89, 95% CI: 0.38–2.03,
P¼ 0.77).
Our analysis confirmed a potential prognostic role for the use of b-
blockers in colorectal cancer patients treated with chemotherapy. Our
findings also suggest a potential worse outcome for patients on b-
blockers receiving bevacizumab. Future prospective studies should
include the incidental use of b-blockers as stratification factor for
clinical outcome.
(Medicine 94(24):e719)
Abbreviations: 5FU = 5fluorouracil, 95% CI = 95% confidence
interval, ABCB1 = ATP-binding cassette, sub-family B1 (gene or
protein encoded), ECOG = Eastern Cooperative Oncology Group,artozzi, MD, Miche MD,
ncesca Ridolfi, MD, and Stefano Cascinu, MDINTRODUCTION
D ifferent growth factors have been shown to possess acrucial role in tumor development and progression. Recent
data suggested that adrenergic activity might also influence
tumor-related biological mechanisms. Both a- and b-adrenergic
stimulation besides a well-known positive inotrope and chrono-
trope effects on cardiac muscle also have a postulated activity as
growth factor. Several analyses in different tumor types, includ-
ing colon cancer, demonstrated that tumor cells might express in
fact either b- or a-adrenergic receptors1: On this basis research-
ers involved hypothesized that adrenergic activity might affect
tumor cells survival and replication. In accordance with these
findings cancer patients receiving incidental b-blockers treat-
ment have been shown to experience an improved outcome.2–10
These data are lacking for metastatic colorectal cancer
patients.2–10
In this latter patients’ population an increasing proportion
of patients will experience arterial hypertension during the
course of their disease, both as preexisting condition (as in
primary hypertension) and as consequence of anticancer treat-
ment (particularly for antiangiogenic treatments). In the present
analysis we evaluated the role of the incidental use of an
antihypertensive therapy (particularly b-blockers) in affecting
clinical outcome for metastatic colorectal cancer patients
receiving first-line treatment.
METHODS
Patients’ Characteristics
The present analysis was designed as retrospective cohort
study that assumed as exposed patients those who were on
incidental b-blockers use as antihypertensive therapy. All con-
secutive metastatic colorectal cancer patients treated with a
first-line regimen including a chemotherapy doublet (capecita-
bine/5FU þ either oxaliplatin or irinotecan)  bevacizumab at
our Institution between 2010 and 2013 were eligible. All
patients received chemotherapy until first radiological evidence
of disease progression, patients’ refusal, or unacceptable
toxicity on an outpatient basis. All relevant patients’ charac-
teristics and follow-up data were collected by patients’
clinical files.
The study was not deemed to be submitted to the local
ethical committee due to the fact that all patients, at the time of
clinical file creation, gave an informed consent for anonymized
clinical data storage and analysis.
Patients were stratified on the basis of antihypertensive
treatment (no treatment vs treatment with b-blockers vs treat-
ment with antihypertensive drugs other than b-blockers). Other
stratification factors were sex, age, performance status at the, previous adjuvant chemotherapy, time
ent (synchronous vs metachronous), sites
ent, k-ras status.
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Study Design
Primary aim of the study was to assess the impact of
incidental b-blockers use on overall survival. Assuming that
risk of death in the first 2 years of therapy was 50% in the cohort
of metastatic colorectal cancer patients treated with a first-line
regimen and that a clinically relevant relative risk of death for
the use of b-blockers was 1.7 times or more, with an a-
probability error at 0.05 and with a power of 0.80, at least
50 patients (25 in either group) were needed.
Overall survival was calculated through Kaplan–Meier
method and was defined as the time between start of treatment
and patients’ death or lost at follow-up, whichever came first.
Progression-free survival was also calculated through
Kaplan–Meier method and was defined as the time between
the start of treatment and the first radiological sign of progressive
disease, patient’s death, or lost at follow-up,whichever came first.
Response rates were evaluated on the basis of RECIST
criteria (ver 1.1) and their association with categorical variables
was assessed through x2 test.
All statistical calculations were performed using MedCalc
Statistical Software version 14.10.2 (MedCalc Software bvba,
Ostend, Belgium; http://www.medcalc.org; 2014).
RESULTS
Patients’ Characteristics
Complete clinical data from 235 patients were available.
Giampieri et alOne hundred twenty-eight patients received a first-line che-
motherapy doublet whereas the remaining 107 received a
chemotherapy doublet þ bevacizumab.
TABLE 1. Characteristics of the 2 Groups of Patients by Main Fa
Chemotherapy-Alone Group (n¼ 128
b-Blockers
Users (n¼ 20)
Not b-Blockers
Users (n¼ 108)
Age (range) 60 (37–84) 61 (38–85)
Sex
Males 16 (80%) 78 (72%)
Females 4 (20%) 30 (28%)
ECOG PS
0–1 18 (90%) 95 (87%)
 2 2 (10%) 13 (13%)
K-ras status
Wild type 13 (65%) 59 (54%)
Mutated 7 (35%) 49 (46%)
Adjuvant chemotherapy
yes 8 (41%) 38 (35%)
not 12 (59%) 70 (65%)
Metastatic sites
1 9 (45%) 35 (32%)
 2 11 (55%) 73 (68%)
Time of metastatic involvement
Synchronous 10 (50%) 60 (55%)
Metachronous 10 (50%) 48 (45%)
Survival
PFS (months) 8.36 7.13
OS (months) 41.3 25.7
ECOG¼Eastern Cooperative Oncology Group, ns¼ not-significant, PF
survival.
2 | www.md-journal.comIn the global population, 142 patients (60%) were not
receiving any antihypertensive treatment, 29 patients (12%)
were on incidental therapy with b-blockers, and 65 patients
(27%) were treated with antihypertensive therapy other than
b-blockers.
In the group of patients treated with a chemotherapy
doublet, 71 patients (55%) were not receiving any antihyper-
tensive treatment, 20 patients (15%) were on treatment with
b-blockers, and 37 patients (28%) were on treatment with other
antihypertensive drugs.
In the bevacizumab treated group, 71 patients (65%) were
not receiving any antihypertensive treatment, 9 (8%) patients
were on treatment with b-blockers, and 28 (25%) were on
treatment with other antihypertensive drugs. Patients groups
were comparable for all clinical factors analyzed (Table 1).
Survival Analysis in the Overall Population
In the overall patients’ population we observed a trend
toward an improved overall survival in patients receiving b-
blockers, although this was not statistically significant (median
OS: 34.4 vs 24.2 months, HR: 1.51, 95% CI: 0.88–2.31,
P¼ 0.14) (Figure 1).
Progression-free survival was also slightly improved in
b-blockers users, although once again this was not statistically
significant (median PFS: 8.86 vs 7.93 months, HR: 1.19, 95%
CI: 0.81–1.72, P¼ 0.38) (Figure 2).
Medicine  Volume 94, Number 24, June 2015Ninety-seven (41%) patients obtained a complete/partial
response. Sixteen responses were observed in the b-blockers
users group, whereas 81 responses were seen in the remaining
ctors of Stratification
) Bevacizumab Group (n¼ 107)
P
value
b-Blockers
users (n¼ 9)
Not b-Blockers
Users (n¼ 98)
P
value
63 (42–85) 60 (37–82)
ns 7 (78%) 60 (62%) ns
ns 2 (22%) 38 (38%) ns
ns 8 (89%) 90 (91%) ns
ns 1 (11%) 8 (9%) ns
ns 3 (33%) 40 (40%) ns
ns 6 (67%) 58 (60%) ns
ns 3 (33%) 44 (45%) ns
ns 6 (67%) 54 (55%) ns
ns 2 (22%) 31 (31%) ns
ns 7 (78%) 67 (69%) ns
ns 5 (56%) 50 (51%) ns
ns 4 (44%) 48 (49%) ns
ns 10.1 8.66 ns
0.03 16 23.7 ns
S¼ progression-free survival, PS¼ performance status, OS¼ overall
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12 patients received calcium channel blockers (mainly lerca-
FIGURE 3. Overall survival in the group of patients treated with-
Medicine  Volume 94, Number 24, June 2015 b-Blockers and Outcome in Colorectal Cancerpatients’ population. This difference was not statistically sig-
nificant (P¼ 0.09).
Survival Analysis According to Treatment
In the group of patients treated with a chemotherapy
doublet, among the 20 b-blockers users we observed a signifi-
cantly improved overall survival (median OS: 41.3 vs 25.7
months, HR: 2.25, 95% CI: 1.04–3.42, P¼ 0.03) (Figure 3).
In the same group of patients, the use of b-blockers was
correlated to a nonstatistically significant trend toward an
improved progression-free survival (median PFS: 8.36 vs
7.13 months, HR: 1.36, 95% CI: 0.85–2.11, P¼ 0.20)
(Figure 4).
Among 20 patients treated with b-blockers, we observed
12 (60%) complete/partial responses, whereas in the remaining
108 patients, we observed 36 (33%) responses (P¼ 0.04).
FIGURE 1. Overall survival in the global population in b-blockers
users (——) compared with non-b-blockers users (___) (34.4 vs
24.2 months, HR: 1.51, 95% CI: 0.88–2.31, P¼0.14).On the other hand in the bevacizumab treated group,
among 9 patients on incidental treatment with b-blockers we
observed a nonsignificant trend toward a worse overall survival
FIGURE 2. Progression-free survival in the global population in b-
blockers users (——) compared with non-b-blockers users (___)
(8.86 vs 7.93 months, HR: 1.19, 95% CI: 0.81–1.72, P¼0.38).
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2.03, P¼ 0.77) (Figure 5).
In the same group of patients, the use of b-blockers demon-
strated a nonstatistically significant trend toward an improved
progression-free survival (median PFS: 10.1 vs 8.66months, HR:
1.35, 95% CI: 0.68–2.53, P¼ 0.40) (Figure 6).
Among the 9 patients treated with b-blockers, we observed
6 (66%) complete/partial responses, whereas in the remaining
98 patients, 43 patients (43%) showed an objective response to
treatment. This difference was not statistically significant
(P¼ 0.06).
Among 70 patients who were not in treatment for high
blood pressure at the start of bevacizumab-based therapy, 38
(54%) experienced hypertension requiring antihypertensive
treatment: 22 patients received diuretics (mainly loop diuretics),
out bevacizumab in b-blockers users (——) comparedwith non-b-
blockers users (___) (41.3 vs 25.7 months, HR: 2.25, 95% CI:
1.04–3.42, P¼0.03).nidipine), the other 4 patients were treated with AT1-
receptor antagonists.
FIGURE 4. Progression-free survival in the group of patients
treatedwithout bevacizumab in b-blockers users (——) compared
with non-b-blockers users (___) (8.36 vs 7.13 months, HR: 1.36,
95% CI: 0.85–2.11, P¼0.20).
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FIGURE 5. Overall survival in the group of patients treated with
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Besides a well-known effect on cardiac outflow, heartbeat
frequency and a general impact on increased blood pressure
adrenaline might affect metabolism and trophism of several
tissues. Adrenaline also showed a role as a growth factor in
many tumor types. Accordingly published data also demon-
strated that cancer cells might express adrenergic receptors.
Abel et al11 demonstrated the presence of b2-adrenergic
receptors on DiFi colon cancer cell line, thus hypothesizing that
adrenergic stimulation may lead to increased proliferation and
enhanced tumor aggressiveness.
Wong et al12 confirmed that observation. In particular, in
colon cancer cell line HT-29, adrenaline determined an increase
in cell proliferation and production of proinflammatory and
proangiogenic factors such as PGE2 and VEGF. This activity
bevacizumab, in b-blockers users (——) compared with non-b-
blockers users (___) (18.5 vs 23.6 months, HR: 0.89, 95% CI:
0.38–2.03, P¼0.77).wasmediated through interaction of adrenaline with both b1 and
b2-receptors, thus further suggesting a potential role of
b-blockers in attenuating tumor aggressiveness.
FIGURE 6. Progression-free survival in the group of patients
treated with bevacizumab, in b-blockers users (——) compared
with non-b-blockers users (___) (10.1 vs 8.66 months, HR: 1.35,
95% CI: 0.68–2.53, P¼0.40).
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lation as chemotherapy resistance factor: In a study of Yao
et al,13 in the HT-29 colon cancer cell line, the levels of ABCB1
gene expression (usually implied to have a role in the phenom-
enon of multidrug resistance) were linked to adrenergic stimu-
lation. Pharmacological a2-adrenergic agonists (such as
yohimbine) determined a net reduction in the levels of ABCB1.
On the other hand, other b-adrenergic inhibitors such as ate-
nolol or a1-inhibitors did not have significant effects on the
expression of the gene.
A further analysis showed a high expression of b-type-
receptors in SW-480 colon cancer cell line.14 In this study,
exposure to norepinephrine determined a clear increase in tumor
cell mobility. The introduction of the nonselective b-blocker
propranolol in the growing medium was able to reverse this
biological phenomenon. On the contrary, the b1-blocker ate-
nolol only marginally influenced the norepinephrine-induced
cancer cell migration.
Other analyses suggested that b-blockers use might nega-
tively influence overall survival. In a study of Shah et al,15
authors observed a slightly decreased survival for b-blockers
users in a series of different tumor types. However, no signifi-
cant impact on survival was observed among the 619 colorectal
cancer patients with the use of either b-blockers alone (103
patients) or b-blockers in combination with other antihyperten-
sive drugs (162 patients) or who were on incidental use of other
antihypertensive drugs (354 patients) (HR: 1.00, 95% CI: 0.77–
1.30).
In another recently published paper, the authors assessed
the impact of b-blockers in a large population-based case-
control study (DACHS study).16 At the multivariate analysis
b-blockers use was not correlated with overall lower risk of
developing colorectal cancer (OR: 1.05, 95% CI: 0.86–1.29).
On the other hand, a higher risk for stage IV colorectal cancer
was observed for patients who were on b-blockers use for more
than 6 years (OR: 2.02, 95% CI: 1.25–3.27).
Our study suggests that incidental b-blockers use could
represent a favorable prognostic factor in the overall population,
whereas in the group of patients who received bevacizumab-
based chemotherapy some caution should be advised.
This apparent discrepancy can be related to the complex
management of hypertension in bevacizumab-treated patients.
In fact there is no conclusive consensus of opinion regarding the
optimal class of antihypertensive drug to be used in this group of
patients, who are on the contrary known to require a careful
evaluation for the possible implication on the clinical out-
come.17
The inhibition of b-adrenergic receptors could also make a
higher concentration of adrenaline available for the interaction
with a-adrenergic receptors.
This group of receptors is usually linked to smooth muscle
contraction, particularly in blood vessels. On the other hand,
bevacizumab is supposed to exert part of its role as inhibitor of
the vascular endothelial growth factor (VEGF) by increasing
nitric oxide concentrations that mediates vasodilatation.18 As a
consequence, the net effect of VEGF inhibition is in the end
similar to the interaction between adrenergic agonists and their
a1-type receptor. An unusual stimulation of a-adrenergic recep-
tors could lead to a reduced delivery of active chemotherapeutic
drugs in a setting where, in the absence of VEGF-inhibition,
chemotherapy would achieve optimal concentrations in tumor
Medicine  Volume 94, Number 24, June 2015tissue.
Although further definitive data are necessary for defini-
tive conclusions, the present analysis seems to suggest that extra
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
attention should be given to the management of patients on
incidental treatment with b-blockers and who are receiving a
bevacizumab-based chemotherapy regimen for metastatic col-
orectal cancer, thus raising the issue of the need of established
guidelines regarding optimal hypertension management in this
group of patients.
REFERENCES
1. Schuller HM. Beta-adrenergic signaling, a novel target for cancer
therapy. Oncotarget. 2010;1:466–469.
2. Powe DG, Entschladen F. Targeted therapies: using b-blockers to
inhibit breast cancer progression. Nat Rev Clin Oncol. 2011;8:
511–512.
3. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast
cancer mortality: a population-based study. J Clin Oncol.
2011;29:2635–2644.
4. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-
blocker use is associated with improved relapse-free survival in
patients with triple-negative breast cancer. J Clin Oncol.
2011;29:2645–2652.
5. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy
reduces secondary cancer formation in breast cancer and improves
cancer specific survival. Oncotarget. 2010;1:628–638.
6. Lemeshow S, Sorensen HT, Phillips G, et al. b-blockers and survival
among Danish patients with malignant melanoma: a population-
based cohort study. Cancer Epidemiol Biomarkers Prev.
2011;20:2273–2279.
7. Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes
with the incidental use of beta blockers among patients with non-
small-cell lung cancer treated with definitive radiation therapy. Ann
Medicine  Volume 94, Number 24, June 20158. Al-Wadei HAN, Ullah MF, Al-Wadei MH. Intercepting neoplastic
progression in lung malignancies via the beta adrenergic ((-AR)
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.pathway: implications for anticancer drug targets. Pharmacol Res.
2012;66:33–40.
9. Schuller HM, Porter B, Riechert A. Beta-adrenergic modulation of
NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin
Oncol. 2000;126:624–630.
10. Lutgendorf SK, Sood AK. Antoni MH Host factors and cancer
progression: biobehavioral signaling pathways and interventions. J
Clin Oncol. 2010;28:4094–4099.
11. Abel PW, Zeng W, Wildrick DM, et al. Characterization of beta-
adrenergic receptors in DiFi and HT-29 cells. Anticancer Res.
1992;12:1655–1658.
12. Wong HP, Ho JW, Koo MW, et al. Effects of adrenaline in human
colon adenocarcinoma HT-29 cells. Life Sci. 2011;88:1108–1112doi:
10.1016/j.lfs.2011.04.007. Epub 2011 Apr 30.
13. Yao H, Duan Z, Wang M, et al. Adrenaline induces chemoresistance
in HT-29 colon adenocarcinoma cells. Cancer Genet Cytogenet.
2009;190:81–87doi: 10.1016/j.cancergencyto.2008.12.009.
14. Masur K, Niggemann B, Zanker KS, et al. Norepinephrine-induced
migration of SW 480 colon carcinoma cells is inhibited by beta-
blockers. Cancer Res. 2001;61:2866–2869.
15. Shah SM, Carey IM, Owen CG, et al. Does b-adrenoceptor blocker
therapy improve cancer survival? Findings from a population-based
retrospective cohort study. Br J Clin Pharmacol. 2011;72:157–
161doi: 10.1111/j.1365-2125.2011.03980.x.
16. Jansen L, Below J, Chang-Claude J, et al. Beta blocker use and
colorectal cancer risk: population-based case-control study. Cancer.
2012;118:3911–3919doi: 10.1002/cncr.26727. Epub 2012 May 14.
17. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension
correlates with clinical outcome in colorectal cancer patients treated
with first-line bevacizumab. Ann Oncol. 2009;20:227–230.
b-Blockers and Outcome in Colorectal CancerOncol. 2013;24:1312–1319. 18. Giampieri R, Scartozzi M, Del Prete M, et al. The ‘‘angiogenetic
ladder’’, step-wise angiogenesis inhibition in metastatic colorectal
cancer. Cancer Treat Rev. 2014;40:934–941.
www.md-journal.com | 5
